<scp>PDE9A</scp> Inhibition Improves Coronary Microvascular Rarefaction and Left Ventricular Diastolic Dysfunction in the <scp>ZSF1</scp> Rat Model of <scp>HFpEF</scp>
Thus, in the ZSF1 rat model of human HFpEF, PDE9A inhibition improves coronary vascular rarefaction and LV diastolic dysfunction, demonstrating the usefulness of PDE9A inhibitors in ameliorating CMD and LV diastolic dysfunction through augmenting PRDX-dependent antioxidant mechanisms.
Authors
- Zsolt Bagi (ORCID: https://orcid.org/0000-0001-8755-2980)
- William M. Pearson
- Katie Anne Fopiano
- Liwei Lang (ORCID: https://orcid.org/0000-0002-2374-645X)
- Saltanat Zhazykbayeva
- Vadym Buncha (ORCID: https://orcid.org/0000-0002-8582-6957)
- Ibrahim El‐Battrawy (ORCID: https://orcid.org/0000-0002-0139-1045)
- Davis Hardell
- Nazha Hamdani
Institutions
- Augusta University (US)
- University Hospitals of the Ruhr-University of Bochum (DE)
- Maastricht University (NL)
- St. Josef-Hospital (DE)
- Ruhr University Bochum (DE)
Publication Details
- Journal
- Microcirculation
- Published
- 2024-09-26
- DOI
- https://doi.org/10.1111/micc.12888
- Citations
- 5
- Primary Topic
- Phosphodiesterase function and regulation
- Type
- article
- Field-Weighted Citation Impact
- 1.17
Funders
- American Heart Association
- Deutsche Forschungsgemeinschaft
- National Institutes of Health